Phenotype of obesity and gastroesophageal reflux disease in the context of comorbidity in patients with cardiovascular diseases
| Autor: | Igor V. Maev, E M Mironova, T V Yureneva-Thorzhevskaya, Georgy Yurenev |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
History
medicine.medical_specialty Endocrinology Diabetes and Metabolism lcsh:Medicine 030209 endocrinology & metabolism Context (language use) Comorbidity Disease leptin Gastroenterology Hiatal hernia Barrett Esophagus 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Obesity gerd Esophagus Abdominal obesity adiponectin Adiponectin business.industry lcsh:R General Medicine medicine.disease digestive system diseases Phenotype medicine.anatomical_structure Cardiovascular Diseases Gastroesophageal Reflux GERD 030211 gastroenterology & hepatology medicine.symptom Family Practice business |
| Zdroj: | Терапевтический архив, Vol 91, Iss 2, Pp 126-133 (2019) |
| ISSN: | 2309-5342 0040-3660 |
| DOI: | 10.26442/00403660.2019.02.000099 |
| Popis: | The relevance of studying such problems as gastroesophageal reflux disease (GERD) and obesity is caused by their high prevalence in the developed countries of the world. Epidemiological data indicate that obesity is a significant risk factor for developing GERD due to increased intra-abdominal pressure and gastroesophageal gradient, slowing of gastric evacuation and formation of hiatal hernia. Abdominal obesity increases the likelihood of complications of GERD: erosive esophagitis, Barrett's esophagus and adenocarcinoma. This fact is connected with humoral influences: increased production of pro-inflammatory cytokines and leptin, and decreased secretion of adiponectin. Treatment of comorbid patients requires higher dosages and longer courses of antisecretory medicines, and an additional prescription of ursodeoxycholic acid. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|